Zapytaj eksperta


Strona główna

Aktualna zawarość koszyka

Twój koszyk jest pusty

Dawkowanie w badaniach NucleVital®Q10

Przewlekła niewydolność krążenia (CHF) - 50-100 [mg/dzień]

- Natural Medicines comprehensive database. Coenzymes Q10 monograph. Available at: , 2003.
- Folkers K., Littarru G.P., Ho L., et al. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch 1970, 40:380-390.
- Folkers K., Vadhanavikit S., Mortensen S.A. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 1985, 82:901-904.
- Mortensen S.A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 2003, 18:79-89.
- Sander S., Coleman C.I., Patel A.A., et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J. Card. Fail. 2006;12:464-472.
- Anonymous. Coenzyme aids cariomyopathy. Med World News, 1985, 8/12: 7) 69.
- Mortensen S.A., Vadhanavikit S., Baandrup U., Folkers K. Long term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exptl. Clin. Res. 1985, 11: 581-593.

Kardiomiopatia - 100 [mg/dzień]

- Langsjoen P.H., Folkers K., Lyson K., et al. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin. Wochenschr. 1988, 66:583-590.
- Langsjoen P.H., Langsjoen P.H., Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1990, 65:521-523.
- Langsjoen P.H., Vadhanavikit S., Folkers K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exptl. Clin. Res. 1985, 11: 577-579.

Choroba niedokrwienna serca - 150-600 [mg/dzień]

- Mattila et all. Coenzymes Q9 and Q10: contents in foods and dietary intake. J. Food Composition Anal. 2001, 14: 409-417.
- Kamikawa T., Kobayashi A., et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am. J. Cardiol. 1985, 56: 247-251.

Ostry zawał serca (AMI) - 120 [mg/dzień]

- Ram B.S., Gurpreet S.W., et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infraction. Cariovascular drugs and Therapy. 1998, Vol. 12, no.4.

Arytmie - 60 [mg/dzień]

- Fujioka T., Sakamato Y., Mimura G. Clinical study of cardiac arrythmias Rusing a 24-hour continuous electrocardiographic recorder (5th report) - antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J. Exp. Med. 1983, 141: 453-463.
- Anonymous. Coenzyme Q10. Monograph. Alt. Med. Rev. 1998, vol.3 no.1.

Wypadanie płatka zastawki mitralnej - 2 [mg/kg/dzień]

- Oda T., Hamamoto K. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jpn. Circ. J. 1984, 48:1387.

Zaburzenia pochodzenia mitochondrialnego - 100-600 [mg/dzień]

- Lenaz G., Fato R., Castelluccio C., Cavazzoni M., Estornell E., Huertas F., et al. An Updating of the biochemical function of Coenzyme Q10 in mitrochondria. Molecular Aspects of Med. 1994,15(1):S29-36.
- Nishikawa Y., Takahashi M., Yorifuji S., et al. Longterm coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome C oxidase deficiency: a 31P NMR study. Neurology 1989, 39:399-403.
- Goda S., Hamada T., Ishimoto S., et al. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol. 1987, 234:62-63.
- Berbel-Garcia A., Barbera-Farre H.R., Etessam J.P., et al. Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitchondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Clin. Neuropharmacol. 2004, 27:187-191.
- Chan A., Reichmann H., Kogel A., et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J. Neurol. 1998, 245:681-685.
- Folkers K., Simonsen R. Two successful doubleblind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim. Biophys. Acta 1995, 1271:281-286.
- Chen R.S., Huang C.C., Chu N.S. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur. Neurol. 1997, 37:212-218.

Dyslipidemia i przyjmowane statyny - 60 [mg/dzień]

- Chapidze G., Kapanadze S., et al. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant. Georgian Med. News, 0:20-5, 2005.

Nadciśnienie - 100-360 [mg/dzień]

- Langsjoen P., Willis R., Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol. Aspects Med. 1994, 15:S265-72.
- Rosenfeldt F.L., Haas S.J., Krum H., et al. Coenzyme Q10 in the treatment of hypertension: a metaanalysis of the clinical trials. J. Hum. Hypertens. 2007, 21:297-306.

Niedobory koenzymu Q10 - 150 [mg/dzień]

- Di Giovanni S., Mirabella M., Spinazzola A., Crociani P., Silvestri G., Broccolini A., et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. American Academy of Neurology, 2001 Aug 14, 57(3):515-8.

Choroba Parkinsona - 300-1200 [mg/dzień]

- Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. of Neurology, 2002 Oct, 59(10):1541-50.
- Muller T., Buttner T., Gholipour A.F., Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson\'s disease. Neurosci Lett 2003;341:201-204.
- Shults C.W., Beal M.F., Fontaine K., et al. Absorption, tolerability and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonsian patients. Neurology, 1998, 50:793-795.

Choroba Huntingtona - 600 [mg/dzień]

- Huntington Study Group. A randomized, placebocontrolled trial of coenzyme Q10 and remacemide in Huntington\'s Disease. Neurology 2001;57:397-404.

Ataxia Friederich`sa - 400 [mg/dzień]

- Hart P.E., Lodi R., et al. Antioxidant treatment o patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 2005, 62: 621-6.

Rak piersi - 90-390 [mg/dzień]

- Lockwood K., Moesgaard S., Yamamoto T., Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem. Biophys. Res. Commun. 1995, 212:172-177.
- Lockwood K., Moesgaard S., Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem. Biophys. Res. Commun. 1994, 199:1504-1508.
- Lockwood K., Moesgaard S., Hanioka T., Folkers K. Apparent partial remission of breast cancer in "high risk" patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Molec. Aspects Med. 1994, 15(Suppl): 231-240.

Chemioterapia - 100-200 [mg/dzień]

- Domae N., Sawada H., Matsuyama E., et al. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep 1981, 65:79-91.
- Karlsson J., Folkers K., Astrum H., et al. Effect of adriamycin on heart and skeletal muscle coenzyme Q (CoQ10) in man. In: Folkers K., Yamamura Y., eds. Biomedical and Clinical Aspects of Coenzyme Q. 1986, Vol.5. 247-256.
- Judy W.V., Hall J.H., Dugan W., et al. Coenzyme Q10 reduction of adriamycin cardiotoxicity. In: Folkers K., Yamamura Y., eds. Biomedical and Clinical Aspects of Coenzyme Q. 1984, Vol. 4. 231-241.
- Roffe L., Schmidt K., Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J. Clin. Oncol. 2004, 22:4418-4424.

Cukrzyca - 200 [mg/dzień]

- Watts G.F., Playford D.A., Croft K.D., et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002, 45:420-426.
- Hodgson J.M., Watts G.F., Playford D.A., et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56:1137-1142.
- Playford D.A., Watts G.F., Croft K.D., Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003, 168: 169-179.

Męska bezpłodność - 200 [mg/dzień]

- Balercia G., Mosca F., Mantero F., et al. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004, 81:93-98.

Immunostymulacja - 60 [mg/dzień]

- Folkers K., Shizukuishi S., Takemura K., et al. Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res. Commun. Chem. Pathol. Pharmacol. 1982, 38: 335-338.

Profilaktyka migreny - 150 [mg/dzień]

- Rozen T.D., Oshinsky M.L., Gebeline C.A., Bradely K.C., Young W.B., Shechter A.L., et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002 Mar, 22(2): 137-41.

Choroby przyzębia - 50 [mg/dzień]

- Mattila et all. Coenzymes Q9 and Q10: contents in foods and dietary intake. J. Food Composition Anal. 2001, 14: 409-417.
- Wilkinson E.G., Arnold R.M., Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res. Commun. Chem. Pathol. Pharmacol. 1976, 14: 715-719.

HIV/AIDS - 200 [mg/dzień]

- Rabing Christensen E., Stegger M., Jensen-Fangel S., et al. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, doubleblind, placebo-controlled pilot study. Clin Infect Dis 2004, 39: 1371-1379.
- Folkers K., Hanioka T., Xia L.J., et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991, 176:786-791.
- Folkers K., Langsjoen P., Nara Y., et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem. Biophys. Res. Commun. 1988, 153: 888-896.

Astma - 120 [mg/dzień]

- Gvozdjakova A., Kucharska J., Bartkovjakova M., et al. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005, 25: 235-240.

Otyłość - 100 [mg/dzień]

- Van Gaal L., de Leeuw I.D., Vadhanavikit S., Folkers K. Exploratory study of coenzyme Q10 in obesity. In Folkers K., Yamamura Y. (eds.). Biomedical and Clinical Aspects of Coenzyme Q. vol.4, Elsevier Publishers, 1984, pp. 369-373.

Efekty fizyczne - 60 [mg/dzień]

- Vanfraecchem J.H.P., Folkers K. Coenzyme Q10 and physical performance. In Folkers K. Biomedical and Clinical Aspects of Coenzyme Q, vol. 3, Elsevier/North-Holland Biomedical Press, Amsterdam, 1981, pp. 235-241.

Ostra niewydolność nerek - 180 [mg/dzień]

- Wilkinson E.G., Arnold R.M., Folkers K., et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975, 12:111-123.

łuszczyca - 50 [mg/dzień]

- Zaira Kharaeva, Elena Gostova, Chiara De Luca, Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition 25 (2009) 295-302.

Redukcja zmarszczek wokół oczu - 60 [mg/dzień]

- T Terada, K Takada, H Yamanishi, Y Ashida Inhibitory effects of coenzyme Q10 on skin aging 5th International CoQ10.

Redukcja zmarszczek twarzy - 60 [mg/dzień]

- Yutaka Ashida, Shoko Kuwazuru, Masaya Nakashima , Kazuo Watabe Effect of Coenzyme Q10 as a Supplement on Wrinkle Reduction FOOD Style 21 2004.6(Vo8.,No.6).

zdrowie mmlodosc odpornosc serce grypa alergia


Wytrzymałość fizyczna - 4 [mg/dzień]
Regulacja gospodarki lipidowej - 12 [mg/dzień]
Obniżenie LDL - 25 [mg/dzień]
Poprawa nawilżenia skóry, poprawa elastyczności skóry - 4 [mg/dzień]
Redukcja zmarszczek - 5 [mg/dzień]
Odnowa włókien kolagenowych - 6 [mg/dzień]
Ochrona przed promieniami UV - 4 [mg/dzień]

- Curt L. Malmsten, Ake Lignell. Dietary Supplementation with Astaxanthin-Rich Algal Meal Improves Strength Endurance - A Double Blind Placebo Controlled Study on Male Students. Carotenoid Science, Vol.13, 2008 - H Yoshida, H Yanai, K Ito, N Sato, N Tada. Astaxanthin administration ameliorates serum lipid and adiponectin levels in subjects within mild hyperlipidemia: a randomized, double-blind, placebocontrolled-study. Atherosclerosis Supplement 2009, Vol. 10, Issue 2 - Graziano Riccioni, MD, Carotenoids and Cardiovascular Disease. Current Atherosclerosis Reports 2009, 11:434?439 - Yamashita, E. carotenoid Sci 11:91-95 (2007). - Capelli B. Astaxanthin. Natural astaxanthin: King of the Carotenoids. - Tominaga, K. et al. in Press.

zdrowie mmlodosc odpornosc serce grypa alergia


Profilaktyka - 5 - 7 [mg/dzień]
Ryzyko powstawania chorób nowotworowych: - 6 - 30 [mg/dzień]
nowotwór płuca - 6,5 - 12 [mg/dzień]
nowotwór prostaty - 15 - 30 [mg/dzień]
nowotwór piersi - 6,2 mg
Męska bezpłodność - 8 - 12 [mg/dzień]
Redukcja cholesterolu LDL - 60[mg/dzień]
Ryzyko powstawania chorób kardiologicznych - 6 - 9 [mg/dzień]
Obniżenie markera nowotworowego skóry - 6 [mg/dzień]
Fotostarzenie skóry - 10-16 [mg/dzień]
Poprawa struktury skóry - 6 [mg/dzień]

- A.V. Rao, L.G. Rao Carotenoids and human health,Pharmacological Research 55 (2007) 207?216 - Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 995;87:1767-1776. - Michaud DS, Feskanich D, Rimm EB, et al. Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts. Am J Clin. Nutr 2000;72:990-997. - Levi F, Pasche C, Lucchini F, La Vecchia C. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer 2001;91:260-263. - Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem. Biophys Res Commun 1997;233:658-662 - H Sesso, S Liu, M Gaziano, J Buring. Dietary lycopene. tomato-based food products and cardiovascular disease in women. J Nutr 133:2336-2341 (July 2003). - Cesarini JP, Michel L, Maurette JM, Adhoute H, Bejot M. 2003. Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. Photodermatol. Photoimmunol. Photomed. 19:182-89. - Lyc-O-Mato 6% Dietary Supplementation Study Protection against Sunburn Cell Formation J Nutr 133:2336-2341 (July 2003). - Stahl et al. J. Nutr. 131: 1449-1451 (2001) - Heinrich U, Tronnier H, Stahl W, Béjot M, Maurette JM. Antioxidant supplements improve parameters related to skin structure in humans. Skin Pharmacol Physiol. 2006;19(4):224-31. Epub 2006 May 4.

zdrowie mmlodosc odpornosc serce grypa alergia

Luteina i zeaksantyna

Profilaktyka - 6 [mg/dzień]
AMD - 6-15 [mg/dzień]
Katarakty - 15 [mg/dzień]
Zwyrodnienie barwnikowe - 40 [mg/dzień]
Skóra i ochrona przed promieniowaniem UV - 8 [mg/dzień]

- Farmakoterapia
- Lutein and Zeaxanthin. Alternative Medicine Review Vol. 10, No 2, 200

zdrowie mmlodosc odpornosc serce grypa alergia

Witamina D3

niemowlęta, dzieci - 400-1000 [IU/dzień]
dorośli - 1000 - 2000 [IU/dzień]
dorośli kobiety w ciąży - 1500 - 2000 [IU/dzień]
matki karmiące - 1500 - 2000 [IU/dzień]

Niedobory, zmniejszenie ryzyka chorób
dzieci (zmniejszenie ryzyka cukrzycy typu I) - 2000 [IU/dzień]
dorośli, nadczynność przytarczyc - 1000 - 2000 [IU/dzień]
dorośli, przewlekle choroby nerek - 3500 [IU/dzień]
dorośli, zespół nerczycowy - 2000 - 4000 [IU/dzień]
dorośli, choroba Parkinsona - 1000 - 3000 [IU/dzień]

- Erik Fink Eriksen, Henning Glerup, Vitamin D deficiency and aging: implications for general health and osteoporosis. Biogerontology 3: 73-77, 2002. - Michael F. Holick Vitamin D and Health: Evolution, Biologic Functions, and Recommended Dietary Intakes for Vitamin D. Clinic Rev Bone Miner Metab (2009) 7:2-19 - Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson\'s disease: a meta-analysis". Lancet Neurol 4 (6): 362?5.

zdrowie mmlodosc odpornosc serce grypa alergia

Witamina E

Profilaktyka - 15 [mg/dzień]
Choroby serca - [32-1500mg/dzień] (średnio 139mg)
Rak prostaty - 267 [mg/dzień]
Jaskra - 300-600 [mg/dzień]
AMD - 333 [mg/dzień]
Choroba Parkinsona - 267 [mg/dzień]

- Food and Nutrition Board, Institute of Medicine, National Academies. - Stampfer MJ i wsp. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993 May 20;328(20):1444-9. - Kirsh VA i wsp. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006 Feb 15;98(4):245-54. - Engin KN, Engin G, Kucuksahin H, Oncu M, Engin G, Guvener B (2007). "Clinical evaluation of the neuroprotective effect of alpha-tocopherol against glaucomatous damage". European journal of ophthalmology 17 (4): 528-33. - Taylor H, Tikellis G, Robman L, McCarty C, McNeil J (2002). "Vitamin E supplementation and macular degeneration: randomised controlled trial". BMJ 325 (7354): 11. - Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson\'s disease: a meta-analysis". Lancet Neurol 4 (6): 362?5.




Ta strona jest przeznaczona dla specjalistów!

Zgodnie z Rozporządzeniem Komisji (UE) Nr 432/2012 z dn. 16 maja 2012 oraz Rozporządzeniem nr 1924/2006 Parlamentu Europejskiego i Rady z dn. 20 grudnia 2006r. z uwagi na zawarte na stronie wyniki badań, treść tej strony przeznaczona jest dla lekarzy, farmaceutów, dietetyków i osób zawodowo zajmujących się żywieniem.

Strony firmy MARINEX zawierają rzetelne informacje, oparte na wynikach badań naukowych przeprowadzanych głównie u ludzi, dotyczące roli jaką pełni odżywianie w funkcjonowaniu organizmu człowieka.